NSCLC-001 · Non-Small Cell Lung Cancer · EGFR/ALK/PD-L1 Engine

PHASES

SORRIES

NPs

Molecular Engine + Treatment

EGFR → Osimertinib FLAURA PROVEN

Exon19del/L858R. PFS 18.9 vs 10.2mo. 3rd-gen TKI standard.

Soria 2018 NEJM FLAURA

ALK → Alectinib ALEX PROVEN

ALK rearrangement ~5%. PFS 34.8 vs 10.9mo vs crizotinib.

Peters 2017 NEJM ALEX

PD-L1≥50% → Pembrolizumab KN-024 PROVEN

1st-line monotherapy no driver. OS 26.3 vs 14.2mo vs chemo.

Reck 2016 NEJM KEYNOTE-024

KRAS G12C → Sotorasib PROVEN

First approved KRAS inhibitor. ORR 37%.

Skoulidis 2021 NEJM CodeBreaK 100

RET/ROS1/NTRK Targeted OPEN

Selpercatinib RET, larotrectinib NTRK. 1-3% each, highly effective.

Drilon 2020 NEJM selpercatinib

Open Sorries — Click to Expand

S-1 SORRY-1 · Osimertinib Acquired Resistance

S-2 SORRY-2 · Brain Mets Penetration Variable

S-3 SORRY-3 · KRAS Non-G12C Undruggable

S-4 SORRY-4 · SCLC Transformation

S-5 SORRY-5 · STK11/KEAP1 Checkpoint Resistance

Biomarkers + Signal

See Phases tab for molecular classification details. Key biomarkers noted in phase gates above.

Novel Patterns

Emerging therapies and patterns logged in PEMCLAU v11. See GREYBACK yang case corpus for yin/yang attack-defense mapping.